All In Biotech

Drug Trial Radar · NCT07110246

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Mar 31, 2032

Study completion Mar 31, 2032

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rising Tide Foundation
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.

Conditions

  • BRAF V600 Mutation
  • Low-grade Glioma
  • Low Grade Glioma of Brain
  • Recurrent Low Grade Glioma

Interventions

  • DabrafenibDrug

    Given orally (PO)

  • TrametinibDrug

    Given PO

  • Magnetic Resonance Imaging (MRI)Procedure

    Undergo imaging by MRI

  • Specimen CollectionProcedure

    Under collection of blood and optional CSF samples

  • Optional Lumbar punctureProcedure

    Undergo optional lumbar puncture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rebound rate (RR)Time frame: Up to a maximum of 34 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana · Recruiting

  • John Hopkins Medical Center

    Baltimore, Maryland · Recruiting

  • St. Louis Children's Hospital Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.